NCT01327950已完成不适用
EPIC SFA - Physician Initiated Trial Investigating the Efficacy of the EPICTM Nitinol Vascular Stent System (Boston Scientific) in Superficial Femoral Lesions: A Prospective, Multi-center Non- Randomized Study - Endoconsul 003
Endovascular Consultoria Limitada6 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2010年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 86
- 试验地点
- 6
- 主要终点
- Evaluate the long-term efficacy and integrity of the EPICTM Nitinol Vascular Stent System in SFA lesions.
研究概览
简要总结
This is a national, prospective, multi-center, non-randomized study to evaluate the long-term efficacy and integrity of the EPICTM Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) lesions. A total of 100 patients will be included in approximately 10 sites. The study is designed to demonstrate the EPIC Nitinol Vascular Stent System is non- inferior to the published patency rates found in the literature. This non-inferiority will be established by proving that the true rate for the EPICTM Nitinol Vascular Stent System is higher than 82% minus a 10% delta.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient presenting with a stenosis, re-stenosis after PTA (or adjunct therapy, excluding stents or stent grafts) or occlusion in the native superficial femoral artery (SFA), or SFA and proximal popliteal artery, suitable for primary stenting;
- •Patient has a score from 2 to 5 following Rutherford classification;
- •Patient is willing to comply with specified follow-up evaluations at the specified times;
- •Patient is at least 18 years old; - Patient (or their legal representative) understands the nature of the procedure and provides written informed consent prior to enrollment in the study;
- •Patient is eligible for treatment with the self-expanding EPIC Nitinol Vascular Stent System
- •If the patient has a contralateral peripheral lesion,this lesion can be treated as a non-target lesion before or after the study procedure
- •If the patient has an ipsilateral iliac lesion,the lesion can be treated as a non target lesion, if the treatment is conducted before the target lesion treatment (during the same procedure or during a previous procedure), with a successful result defined as less than 30% residual diameter stenosis
- •Angiographic Inclusion Criteria:
- •Target lesion(s) location is situated in the native SFA or SFA and proximal popliteal artery, with its most proximal point at least 1cm below the origin of the deep femoral artery and its distal point at least 3cm proximal to the knee joint, as measured by ipsilateral oblique view for proximal lesions and straight posterioanterior (PA) view for distal lesions;
- •Evidence of at least 50% stenosis, re-stenosis after PTA (or adjunct therapy, excluding stents or stent grafts) or occlusion in the target lesion;
- •Target lesion(s) total length is minimally 4cm and maximally 11cm and is amenable to treatment with a single stent;
- •Target vessel diameter visually estimated is > 4mm and < 6.5mm
- •There is angiographic evidence of at least one-vessel-runoff to the foot
排除标准
- •Presence of another stent or stent graft in the target vessel that was placed during a previous procedure;
- •Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis;
- •Previous bypass surgery in the same limb; - Necessity to treat target vessel with more than one EPICTM stent;
- •Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated;
- •Patient has bleeding diathesis, coagulopathy, known hypercoagulable condition or refuses blood transfusion;
- •Patients with known hypersensitivity to nickel-titanium;
- •Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding;
- •Life expectancy of less than twelve months;
- •Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure;
- •Use of cutting balloon, scoring balloon, thrombectomy, arthrectomy, brachytherapy or laser devices during procedure;
- •Any patient considered to be hemodynamically unstable at onset of procedure;
- •Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period;
- •Patient presenting one of the following comorbid conditions: hemodialysis, elevated creatine levels (> 2.5mg/dl), recent MI or hemorrhagic stroke occurrence (both within 30 days).
- •Angiographic Exclusion Criteria:
- •Inability to cross the target lesion by means of an exchangeable guidewire and to re-enter the true vessel lumen distal to the lesion site;
- •Presence of a significant (minimally 50%) stenosis or occlusion in the ipsilateral common femoral artery;
- •Aneurysm located at the level of the to-be-treated artery; - Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site; - Perforation (evidenced by extravasation of contrast medium), dissection or other injury of the access or target vessel requiring additional stenting or surgery prior to the start of the index procedure;
- •Focal popliteal artery disease in the absence of femoral disease.
结局指标
主要结局
Evaluate the long-term efficacy and integrity of the EPICTM Nitinol Vascular Stent System in SFA lesions.
时间窗: 12 months
The primary endpoint is primary patency rate at 12 months as determined by Duplex ultrasound at twelve months, defined as a target vessel with \<50% diameter stenosis at twelve months (systolic velocity ratio no greater than 2.4), without occurrence of target lesion revascularization between the index procedure and the twelve months follow-up control
次要结局
- Initial arteriographic success(immediately following stent implantation (day 1))
- Primary patency rate(6 months)
- Major adverse event(1 year)
- Increase of ABI(1 year)
- Technical Success(immediately following stent implantation (day 1))
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
HAART Model 300 Annuloplasty RingAortic RegurgitationNCT01400841Biostable Science & Engineering18
Unknown
不适用
An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)Rheumatoid ArthritisNCT01194401Hoffmann-La Roche3,404
已完成
不适用
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real WorldGastrointestinal Stromal TumorsNCT05381753CStone Pharmaceuticals61
尚未招募
不适用
Biomarkers of Traumatic Brain Injury With Tbit SystemBrain Injuries, TraumaticNCT04107662BioDirection Inc740
已完成
不适用
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in GreeceAdvanced Soft Tissue SarcomaNCT02618122Genesis Pharma S.A.63